Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Shoichi Kinoshita

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2698-1153; OpenAlex author ID A5090096487. Sources: OpenAlex.

Their work

Papers
17
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 8 papers · 2016: 5 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 17

  1. Clinical significance and therapeutic implication of CD200 in pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.10.007↗
  2. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively … Co-author DOI 10.1007/s00268-018-4814-4↗
  3. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreati… Co-author DOI 10.1002/jhbp.318↗
  4. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. Co-author DOI 10.1002/jhbp.320↗
  5. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic … Co-author DOI 10.1007/s00280-015-2928-z↗
  6. Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2015.10.034↗
  7. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Grou… Co-author DOI 10.1097/mpa.0000000000000579↗
  8. Importance of resectability status in neoadjuvant treatment for pancreatic cancer. Co-author DOI 10.1002/jhbp.258↗
  9. Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. Co-author DOI 10.1007/s00268-015-3205-3↗
  10. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1007/s00423-015-1304-0↗
  11. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. Co-author DOI 10.1007/s00535-014-1005-4↗
  12. Potential role of surgical resection for pancreatic cancer in the very elderly. Co-author DOI 10.1016/j.pan.2015.03.015↗
  13. Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000395↗
  14. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. Co-author DOI 10.1186/s13046-015-0144-7↗
  15. Clinical significance of CD155 expression in human pancreatic cancer. Co-author PMID 25862891↗
  16. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. Co-author DOI 10.1007/s00534-012-0532-8↗
  17. [Resection of the remnant pancreas for recurrent pancreatic cancer after distal pancreatectomy-a case report]. Co-author PMID 23267918↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Sho · 17 shared papers, 2012–2024 · strength 0.94
  2. Minako Nagai · 13 shared papers, 2015–2024 · strength 0.76
  3. Takahiro Akahori · 15 shared papers, 2012–2016 · strength 0.67
  4. Yoshiyuki Nakajima · 14 shared papers, 2012–2016 · strength 0.63
  5. Satoshi Nishiwada · 11 shared papers, 2015–2016 · strength 0.52
  6. Satoshi Yasuda · 6 shared papers, 2012–2024 · strength 0.39
  7. Hiroaki Yanagimoto · 7 shared papers, 2015–2019 · strength 0.35
  8. Sohei Satoi · 7 shared papers, 2015–2019 · strength 0.35
  9. Kimihiko Kichikawa · 6 shared papers, 2013–2016 · strength 0.27
  10. Yoshiaki Murakami · 4 shared papers, 2015–2019 · strength 0.21
  11. Masanao Kurata · 4 shared papers, 2015–2019 · strength 0.21
  12. Hiroki Yamaue · 4 shared papers, 2015–2019 · strength 0.21
  13. Kenichiro Uemura · 4 shared papers, 2015–2019 · strength 0.21
  14. Takumi Fukumoto · 4 shared papers, 2015–2019 · strength 0.21
  15. Ippei Matsumoto · 4 shared papers, 2015–2019 · strength 0.21
  16. Michiaki Unno · 4 shared papers, 2015–2019 · strength 0.21
  17. Fuyuhiko Motoi · 4 shared papers, 2015–2019 · strength 0.21
  18. Goro Honda · 4 shared papers, 2015–2019 · strength 0.21
  19. Chiho Ohbayashi · 4 shared papers, 2015–2016 · strength 0.20
  20. Kota Nakamura · 1 shared paper, 2024 · strength 0.19
  21. Yuichiro Kohara · 1 shared paper, 2024 · strength 0.19
  22. Taichi Terai · 1 shared paper, 2024 · strength 0.19
  23. Tomohisa Yamamoto · 4 shared papers, 2015–2016 · strength 0.19
  24. Toshihiro Tanaka · 4 shared papers, 2013–2016 · strength 0.18
  25. Hideyuki Nishiofuku · 4 shared papers, 2013–2016 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.